Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Dunad Therapeutics has raised $24.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.
Dunad Therapeutics's investors include Epidarex Capital, Novartis, BioGeneration Ventures.
Dunad Therapeutics is headquartered in London, United Kingdom.
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Dunad Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dunad Therapeutics — Funding & Investors." VCBacked, November 2, 2021, https://www.vcbacked.co/company/dunad-therapeutics. Accessed September 30, 2026.
VCBacked. (2021). Dunad Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/dunad-therapeutics
{{cite web |title=Dunad Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dunad-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated